Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP-TRX signaling
To investigate the ROS1 and FAK inhibitors combination may provide stronger anti-cancer effects by targeting CDH1 deficiency and potentially overcome drug resistance. Here, we evaluated the effects and mechanisms of combined treatment with FAK inhibitor IN10018 and ROS1 inhibitors. Overall design: Comparative gene expression profiling analysis of RNA-seq data for NUGC-4 cells by fifferent treament (IN10018 or Crizotinib monotherapy, IN10018 and Crizotinib combination)